AGC Biologics grows pDNA, mRNA production abilities at Heidelberg site
Expansion at German facility features new GMP manufacturing lines and a cleanroom, among other additions
AGC Biologics, a contract development and manufacturing organization (CDMO), will be expanding its Heidelberg facility, as it looks to increase manufacturing capacities for plasmid DNA (pDNA) and messenger RNA (mRNA) projects.
With this expansion, AGC Biologics is enhancing its current 100L and 1,000L manufacturing capacities for different biologics projects by adding an additional good manufacturing practice (GMP) manufacturing line. The expansion includes a new GMP cleanroom for mRNA development and manufacturing, a new process development lab for microbial protein and cell and gene therapy (C>) projects, along with extra warehouse room.
The facility's new features will be fully operational by 2023.
“This investment helps strengthen our existing pDNA capabilities and supports our entry into the mRNA space,” says Patricio Massera, AGC Biologics CEO. “With the global pDNA and mRNA markets experiencing record growth, we are focused on ensuring our facilities worldwide offer innovative services that meet the needs of therapeutics developers.”
The effort to increase the capabilities of the Heidelberg facility follows a series of other moves towards growth that the CDMO has made over the past few months, including the construction of a new Danish facility in Copenhagen and the purchase of a C> facility in Longmont, CO.
